Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)

This study has been completed.
Sponsor:
Information provided by:
Anacor Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00679601
First received: May 15, 2008
Last updated: NA
Last verified: May 2008
History: No changes posted
  Purpose

The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.


Condition Intervention Phase
Onychomycosis
Drug: AN2690
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients With Moderate to Severe Onychomycosis

Resource links provided by NLM:


Further study details as provided by Anacor Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Plasma concentration of AN2690 in plasma and the concentration of AN2690 in urine over time [ Time Frame: Days 0, 1, 14, 15, and 28 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Efficacy measures of linear toenail growth, fungal culture results, KOH results, and clear toenail growth [ Time Frame: Days 0, 14, 28, and 42 ] [ Designated as safety issue: No ]
  • Safety and tolerance assessed by application site reactions, adverse events, vital signs, physical examinations, and 12-lead EKG [ Time Frame: Days 0-28, and 42 ] [ Designated as safety issue: Yes ]

Enrollment: 20
Study Start Date: March 2007
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: AN2690
    AN2690 7.5% Solution, once daily for 28 days
Detailed Description:

A single center, open-label, multiple-dose study design will be used. Planned enrollment is 20 subjects to complete 15. Subjects must have a clinical diagnosis of onychomycosis of each great toenail and a clinical diagnosis of onychomycosis of six of the remaining toenails.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female ≥18 and ≤65
  • BMI between 18.5 and 35 inclusive
  • Moderate to severe onychomycosis involving ≥80% of both great toenails, as determined by visual inspection after the nail has been trimmed
  • Combined thickness of the nail plate and nail bed of each great toenail is >3mm
  • At least 6 additional toenails with a clinical diagnosis of onychomycosis
  • If a female of childbearing potential, must be using of a highly effective method of birth control or abstinence and be willing to remain on that same method of birth control throughout the study
  • Capable of understanding and signing the informed consent, and willing to comply with all requirements of the study

Exclusion Criteria:

  • History of allergy to any of the study drug or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
  • Clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety
  • Diabetes mellitus requiring treatment other than diet and exercise
  • Willing to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study
  • Nursing, pregnant or planning to become pregnant during the study
  • Failure to complete the specified washout period(s) for the following topical:

    1. Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study): 4 weeks
    2. Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
  • Failure to complete the specified washout period(s) for the following systemic medications:

    1. Corticosteroids (including intramuscular injections): 2 weeks
    2. Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophyte: 24 weeks
    3. Systemic immunomodulators: 4 weeks
  • Received treatment of any type for cancer within the last 6 months
  • History of any significant internal disease
  • Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
  • AIDS or AIDS related complex
  • History of street drug or alcohol abuse
  • Donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six-week period preceding study initiation
  • Donated plasma during the two week period preceding study initiation
  • Participated in any other trial of an investigational drug or device within 30 days prior to enrollment or participation in a research study concurrent with this study
  • Prior enrollment in a study using the study drug, AN2690
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00679601

Locations
United States, Texas
J&S Studies
Bryan, Texas, United States, 77802
Sponsors and Collaborators
Anacor Pharmaceuticals, Inc.
Investigators
Study Director: Karl Beutner, MD, PhD Anacor Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Karl Beutner, MD, PhD, Chief Medical Officer, Anacor Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00679601     History of Changes
Other Study ID Numbers: AN2690-ONYC-205
Study First Received: May 15, 2008
Last Updated: May 15, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Anacor Pharmaceuticals, Inc.:
Onychomycosis
Fungal Nail

Additional relevant MeSH terms:
Onychomycosis
Tinea
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Nail Diseases
Skin Diseases

ClinicalTrials.gov processed this record on April 16, 2014